Literature DB >> 2464543

Individuals infected with HIV possess antibodies against IL-2.

K L Bost1, B H Hahn, M S Saag, G M Shaw, D A Weigent, J E Blalock.   

Abstract

Studies are presented here which demonstrate that antibodies reacting with human interleukin-2 (IL-2) are present in the sera of patients infected with the human immunodeficiency virus (HIV). It is likely that these antibodies are present due to a homology between the HIV envelope protein and IL-2. The homologues are six amino acids in length corresponding to the carboxy terminus of gp41, Leu-Glu-Arg-Ile-Leu-Leu (LERILL), and residues 14-19 of secreted IL-2, Leu-Glu-His-Leu-Leu-Leu (LEHLLL). Thus, we questioned whether antibodies made against this HIV envelope peptide would cross-react with IL-2. Not only do a high percentage of the HIV-infected individuals tested here have antibodies against LERILL, but these antibodies cross-react with the IL-2 sequence, LEHLLL. Additional antigenic processing of IL-2 is suggested by the finding that epitopes other than this sixmer are also recognized by antibodies in patients' sera. Thus, these studies suggest a mechanism by which infection with HIV can induce a potentially suppressive autoimmune response. Specifically, antibodies against an HIV envelope peptide cross-react with an epitope in IL-2.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2464543      PMCID: PMC1385572     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  13 in total

1.  The HTLV-III envelope protein contains a hexapeptide homologous to a region of interleukin-2 that binds to the interleukin-2 receptor.

Authors:  D A Weigent; P D Hoeprich; K L Bost; T K Brunck; W E Reiher; J E Blalock
Journal:  Biochem Biophys Res Commun       Date:  1986-08-29       Impact factor: 3.575

2.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.

Authors:  B R Starcich; B H Hahn; G M Shaw; P D McNeely; S Modrow; H Wolf; E S Parks; W P Parks; S F Josephs; R C Gallo
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

3.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

4.  The Walter Reed staging classification for HTLV-III/LAV infection.

Authors:  R R Redfield; D C Wright; E C Tramont
Journal:  N Engl J Med       Date:  1986-01-09       Impact factor: 91.245

Review 5.  Interleukin 2.

Authors:  K A Smith
Journal:  Annu Rev Immunol       Date:  1984       Impact factor: 28.527

6.  Regions of complementarity between the messenger RNAs for epidermal growth factor, transferrin, interleukin-2 and their respective receptors.

Authors:  K L Bost; E M Smith; J E Blalock
Journal:  Biochem Biophys Res Commun       Date:  1985-05-16       Impact factor: 3.575

7.  Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS.

Authors:  B H Hahn; G M Shaw; M E Taylor; R R Redfield; P D Markham; S Z Salahuddin; F Wong-Staal; R C Gallo; E S Parks; W P Parks
Journal:  Science       Date:  1986-06-20       Impact factor: 47.728

8.  Three-dimensional structure of interleukin-2.

Authors:  B J Brandhuber; T Boone; W C Kenney; D B McKay
Journal:  Science       Date:  1987-12-18       Impact factor: 47.728

9.  Structure and expression of a cloned cDNA for human interleukin-2.

Authors:  T Taniguchi; H Matsui; T Fujita; C Takaoka; N Kashima; R Yoshimoto; J Hamuro
Journal:  Nature       Date:  1983 Mar 24-30       Impact factor: 49.962

10.  Antibodies to interleukin 2. Effects on immune responses in vitro and in vivo.

Authors:  A Granelli-Piperno; L Andrus; E Reich
Journal:  J Exp Med       Date:  1984-09-01       Impact factor: 14.307

View more
  9 in total

1.  Serum non-organ specific autoantibodies in human immunodeficiency virus 1 infection.

Authors:  F Cassani; L Baffoni; E Raise; L Selleri; M Monti; L Bonazzi; F M Gritti; F B Bianchi
Journal:  J Clin Pathol       Date:  1991-01       Impact factor: 3.411

2.  HIV-associated myocarditis. Pathology and immunopathology.

Authors:  W E Beschorner; K Baughman; R P Turnicky; G M Hutchins; S A Rowe; A L Kavanaugh-McHugh; D L Suresch; A Herskowitz
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

Review 3.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

4.  Detection of autoantibodies to cytokines.

Authors:  K Bendtzen; M B Hansen; C Ross; M Svenson
Journal:  Mol Biotechnol       Date:  2000-03       Impact factor: 2.695

5.  Binding of cytokines to pharmaceutically prepared human immunoglobulin.

Authors:  M Svenson; M B Hansen; K Bendtzen
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

6.  Autoantibodies to the alpha/beta T-cell receptors in human immunodeficiency virus infection: dysregulation and mimicry.

Authors:  D F Lake; S F Schluter; E Wang; R M Bernstein; A B Edmundson; J J Marchalonis
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

7.  Differential isotype expression and binding properties of T cell-reactive antibodies in human immunodeficiency virus (HIV) infection.

Authors:  F Silvestris; C Azzolini; F Dammacco
Journal:  J Clin Immunol       Date:  1992-03       Impact factor: 8.317

8.  Clinical Relevance of Autoantibodies against Interleukin-2 in Patients with Systemic Lupus Erythematosus.

Authors:  Miao Shao; Xiao-Lin Sun; He Sun; Jing He; Rui-Jun Zhang; Xia Zhang; Zhan-Guo Li
Journal:  Chin Med J (Engl)       Date:  2018-07-05       Impact factor: 2.628

9.  Lack of Evidence for Molecular Mimicry in HIV-Infected Subjects.

Authors:  Peter D Burbelo; James S Klimavicz; Steve G Deeks; Joseph A Kovacs; Jack A Ragheb
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.